Matrix Metalloproteinase Inhibitors in Cancer Therapy:
The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Ca...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2001
|
| Schriftenreihe: | Cancer Drug Discovery and Development
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics |
| Beschreibung: | 1 Online-Ressource (XIII, 262 p. 29 illus., 3 illus. in color) |
| ISBN: | 9781592590117 |
| DOI: | 10.1007/978-1-59259-011-7 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145918 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592590117 |9 978-1-59259-011-7 | ||
| 024 | 7 | |a 10.1007/978-1-59259-011-7 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-59259-011-7 | ||
| 035 | |a (OCoLC)1119023541 | ||
| 035 | |a (DE-599)BVBBV046145918 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XH 3300 |0 (DE-625)152889:13129 |2 rvk | ||
| 245 | 1 | 0 | |a Matrix Metalloproteinase Inhibitors in Cancer Therapy |c edited by Neil J. Clendeninn, Krzysztof Appelt |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2001 | |
| 300 | |a 1 Online-Ressource (XIII, 262 p. 29 illus., 3 illus. in color) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Drug Discovery and Development | |
| 520 | |a The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Metalloproteinaseninhibitor |0 (DE-588)4305228-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | 2 | |a Metalloproteinaseninhibitor |0 (DE-588)4305228-9 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Clendeninn, Neil J. |4 edt | |
| 700 | 1 | |a Appelt, Krzysztof |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781617371233 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468496031 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780896036680 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59259-011-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526103 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-1-59259-011-7 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180483188195328 |
|---|---|
| any_adam_object | |
| author2 | Clendeninn, Neil J. Appelt, Krzysztof |
| author2_role | edt edt |
| author2_variant | n j c nj njc k a ka |
| author_facet | Clendeninn, Neil J. Appelt, Krzysztof |
| building | Verbundindex |
| bvnumber | BV046145918 |
| classification_rvk | XH 3300 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-59259-011-7 (OCoLC)1119023541 (DE-599)BVBBV046145918 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-59259-011-7 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03311nmm a2200541zc 4500</leader><controlfield tag="001">BV046145918</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592590117</subfield><subfield code="9">978-1-59259-011-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59259-011-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-59259-011-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119023541</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145918</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3300</subfield><subfield code="0">(DE-625)152889:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Matrix Metalloproteinase Inhibitors in Cancer Therapy</subfield><subfield code="c">edited by Neil J. Clendeninn, Krzysztof Appelt</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIII, 262 p. 29 illus., 3 illus. in color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Drug Discovery and Development</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Metalloproteinaseninhibitor</subfield><subfield code="0">(DE-588)4305228-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Metalloproteinaseninhibitor</subfield><subfield code="0">(DE-588)4305228-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clendeninn, Neil J.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Appelt, Krzysztof</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781617371233</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468496031</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780896036680</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59259-011-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526103</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59259-011-7</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145918 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:28Z |
| institution | BVB |
| isbn | 9781592590117 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526103 |
| oclc_num | 1119023541 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIII, 262 p. 29 illus., 3 illus. in color) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Cancer Drug Discovery and Development |
| spelling | Matrix Metalloproteinase Inhibitors in Cancer Therapy edited by Neil J. Clendeninn, Krzysztof Appelt Totowa, NJ Humana Press 2001 1 Online-Ressource (XIII, 262 p. 29 illus., 3 illus. in color) txt rdacontent c rdamedia cr rdacarrier Cancer Drug Discovery and Development The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Metalloproteinaseninhibitor (DE-588)4305228-9 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Therapie (DE-588)4059798-2 s Metalloproteinaseninhibitor (DE-588)4305228-9 s 1\p DE-604 Clendeninn, Neil J. edt Appelt, Krzysztof edt Erscheint auch als Druck-Ausgabe 9781617371233 Erscheint auch als Druck-Ausgabe 9781468496031 Erscheint auch als Druck-Ausgabe 9780896036680 https://doi.org/10.1007/978-1-59259-011-7 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Matrix Metalloproteinase Inhibitors in Cancer Therapy Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd Therapie (DE-588)4059798-2 gnd Metalloproteinaseninhibitor (DE-588)4305228-9 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4059798-2 (DE-588)4305228-9 |
| title | Matrix Metalloproteinase Inhibitors in Cancer Therapy |
| title_auth | Matrix Metalloproteinase Inhibitors in Cancer Therapy |
| title_exact_search | Matrix Metalloproteinase Inhibitors in Cancer Therapy |
| title_full | Matrix Metalloproteinase Inhibitors in Cancer Therapy edited by Neil J. Clendeninn, Krzysztof Appelt |
| title_fullStr | Matrix Metalloproteinase Inhibitors in Cancer Therapy edited by Neil J. Clendeninn, Krzysztof Appelt |
| title_full_unstemmed | Matrix Metalloproteinase Inhibitors in Cancer Therapy edited by Neil J. Clendeninn, Krzysztof Appelt |
| title_short | Matrix Metalloproteinase Inhibitors in Cancer Therapy |
| title_sort | matrix metalloproteinase inhibitors in cancer therapy |
| topic | Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd Therapie (DE-588)4059798-2 gnd Metalloproteinaseninhibitor (DE-588)4305228-9 gnd |
| topic_facet | Oncology Oncology Krebs Medizin Therapie Metalloproteinaseninhibitor |
| url | https://doi.org/10.1007/978-1-59259-011-7 |
| work_keys_str_mv | AT clendeninnneilj matrixmetalloproteinaseinhibitorsincancertherapy AT appeltkrzysztof matrixmetalloproteinaseinhibitorsincancertherapy |